Increased levels of sirtuin-1 in systemic lupus erythematosus.
biomarker
lupus
sirtuin-1
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
02
05
2022
received:
08
03
2022
accepted:
17
05
2022
pubmed:
2
6
2022
medline:
24
8
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
We investigated plasma sirtuin-1 (SIRT1) levels in systemic lupus erythematosus (SLE) patients, and discussed potential of plasma SIRT1 as a biomarker for SLE. A total of 359 subjects, including 299 patients (89 SLE, 50 rheumatoid arthritis, 30 osteoarthritis, 30 gout, 38 Sjögren's syndrome, 20 ankylosing spondylitis, 30 mixed connective tissue disease, 12 systemic sclerosis) and 60 healthy controls were recruited. SIRT1 in plasma of SLE patients was detected by enzyme-linked immunosorbent assay. Relationship between SIRT1 levels, clinical, laboratory characteristics in SLE patients was discussed. Plasma SIRT1 to discriminate SLE from different rheumatic patients and healthy controls was assessed by receiver operating characteristic (ROC) curve analysis. SIRT1 levels were elevated in SLE patients compared with healthy controls (6.28 [5.89-6.68] vs 2.42 [2.10-2.74] ng/mL, P < .001). SIRT1 concentration in plasma was significantly associated with disease activity (r Circulating SIRT1 was elevated in SLE, and might be a promising SLE diagnostic marker.
Identifiants
pubmed: 35644944
doi: 10.1111/1756-185X.14360
doi:
Substances chimiques
Biomarkers
0
SIRT1 protein, human
EC 3.5.1.-
Sirtuin 1
EC 3.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-876Subventions
Organisme : National Natural Science Foundation of China
ID : 81701606
Informations de copyright
© 2022 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Consiglio CR, Juliana da Silveira S, Monticielo OA, Xavier RM, Brenol JCT, Chies JAB. SIRT1 promoter polymorphisms as clinical modifiers. On systemic lupus erythematosus. Mol Biol Rep. 2014;41(7):4233-4239.
Chi M, Ma K, Li Y, et al. Immunological involvement of MicroRNAs in the key events of systemic lupus erythematosus. Front Immunol. 2021;12:699684.
Gautam P, Shrama A, Bhatnagar A. Global histone modification analysis reveals hypoacetylated H3 and H4 histones in B cells from systemic lupus erythematosus patients. Immunol Lett. 2021;240:41-45.
Hu N, Qiu X, Luo Y, et al. Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol. 2008;35(5):804-810.
Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res. 2005;4(6):2032-2042.
Bosisio D, Vulcano M, Del Prete A, et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol. 2008;84(6):1540-1548.
Lu X, Kovalev GI, Chang H, et al. Inactivation of NuRD component Mta2 causes abnormal T cell activation and lupus-like autoimmune disease in mice. J Biol Chem. 2008;283(20):13825-13833.
Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin a reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA. 2001;98(5):2628-2633.
Hu N, Long H, Zhao M, Yin H, Lu Q. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice. Scand J Rheumatol. 2009;38(6):464-471.
Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell. 2004;16(1):93-105.
Kong S, McBurney MW, Fang D. Sirtuin 1 in immune regulation and autoimmunity. Immunol Cell Biol. 2012;90(1):6-13.
Vratsanos GS, Jung S, Park YM, Craft J. CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med. 2001;193(3):329-337.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.
Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the american rheumatism association. Arthritis Rheum. 1986;29(8):1039-1049.
Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2015;67(10):2557-2568.
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheum. 2017;69(1):35-45.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.
Alarcón-Segovia D. Symptomatic Sjögren’s syndrome in mixed connective tissue disease. J Rheumatol. 1984;11(5):582-583.
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747.
Ugarte-Gil M, Gamboa-Cárdenas R, Reátegui-Sokolova C, et al. Better health-related quality of life in systemic lupus erythematosus predicted by low disease activity state/remission: data from the Peruvian Almenara lupus cohort. Arthritis Care Res. 2020;72(8):1159-1162.
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75(9):1615-1621.
Kwon HS, Brent MM, Getachew R, et al. Human immunodeficiency virus type 1 tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe. 2008;3(3):158-167.
Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123(3):437-448.
Zhang M, Zhang Q, Hu Y, et al. miR-181a increases FoxO1 acetylation and promotes granulosa cell apoptosis via SIRT1 downregulation. Cell Death Dis. 2017;8(10):e3088.
Niederer F, Ospelt C, Brentano F, et al. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis. 2011;70(10):1866-1873.
Sarumaru M, Watanabe M, Inoue N, et al. Association between functional SIRT1 polymorphisms and the clinical characteristics of patients with autoimmune thyroid disease. Autoimmunity. 2016;49(5):329-337.
Li R, Sun X, Shu Y, et al. Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients. J Neuroimmunol. 2017;313:56-60.
Nan H, Qing L, Qinqin X, et al. Expression of silence information regulator1(sirt1) in B cells in peiipheral venous blood of subacuteous lupus serythematosus. J Chin Phy. 2015;17(12):1836-1838.
Olivares D, Perez-Hernandez J, Forner MJ, et al. Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis. Clin Sci. 2018;132(5):569-579.
Sequeira J, Boily G, Bazinet S, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res. 2008;314(16):3069-3074.
Wang Q, Yan C, Xin M, Han L, Zhang Y, Sun M. Sirtuin 1 (Sirt1) overexpression in BaF3 cells contributes to cell proliferation promotion, apoptosis resistance and pro-inflammatory cytokine production. Med Sci Monit. 2017;23:1477-1482.
Yoshizaki T, Schenk S, Imamura T, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;298(3):E419-E428.
Guo NH, Fu X, Zi FM, Song Y, Wang S, Cheng J. The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. Int Immunopharmacol. 2019;73:181-192.
Pan F, Li YJ, Lu Y. Panax notoginseng saponins reverse P-gp-mediated steroid resistance in lupus: involvement in the suppression of the SIRT1/FoxO1/MDR1 signalling pathway in lymphocytes. BMC Complement Med Ther. 2022;22(1):13.
Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017;28(1):4-12.
Pisetsky DS, Bossuyt X, Meroni PL. ANA as an entry criterion for the classification of SLE. Autoimmun Rev. 2019;18(12):102400.